PASSPORT

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Topic / Pathology

  • Progressive Supranuclear Palsy (PSP)

Objectives

To have more informations, click on the link below:

https://clinicaltrials.gov/ct2/show/NCT03068468?term=passport&cond=PSP&draw=2&rank=1

Sponsor

Biogen

Scientific publication(s)

  • Dam T et al; PASSPORT Study Group. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021 Aug;27(8):1451-1457. doi: 10.1038/s41591-021-01455-x. Epub 2021 Aug 12. Erratum In: Nat Med. 2022 Oct 17.

    https://pubmed.ncbi.nlm.nih.gov/34385707/

Status

Published results

Participating centers

Share

Updated on 17 February 2023